Blackhawk Growth Corp. announced that it continues to sell the SARS-CoV-2 IgG /IgM Rapid Test Kits and the ExProbe SARS-CoV-2 Testing Kits. Blackhawk is still awaiting Health Canada interim order to allow for sales of the kits within Canada, as outlined below, but continues to grow the sale of the kits in jurisdictions outside of Canada. Since entering definitive distribution agreements (the "Distribution Agreement") to distribute certain diagnostic products, including the ExProbe SARS-CoV-2 Testing Kit and a SARS-CoV-2 IgG/IgM Rapid Test Kit (collectively, the "Test Kits") used in the detection associated with COVID-19, Blackhawk has sold over 5,000 Test Kits with gross sales revenue of approximately USD 75,000. Sales of the Test Kits have been focused on the United States market. Blackhawk expects the sales to continue to grow as the Covid-19 virus numbers of infections and required testing reaches critical levels in numerous States in the US. With the success of the Blackhawk sales efforts, the distribution agreement has been mutually extended. In addition, Blackhawk continues to provide the required information to Health Canada in the hopes that it receives the approval to provide the Test Kits throughout Canada. The Health Canada Interim Order ("IO") for its SARS-CoV-2 IgG /IgM Rapid Test Kit application was submitted on November 4th, 2020 and the Company received a "request for additional information" letter from Health Canada on November 12th. In order to provide a full & comprehensive response to Health Canada materials requested by Health Canada were completed and submitted on December 13th, 2020. The Health Canada Interim Order ("IO") for its ExProbe SARS-CoV-2 Testing Kit was completed and submitted November 13th 2020 and is currently listed as "Under Review". Both the ExProbe SARS-CoV-2 and SARS-CoV-2 IgG /IgM Rapid Test Kit are currently USA FDA EUA Authorized and carry a CE mark overseas. Blackhawk makes no representations or provides any guarantees on Health Canada's review timelines.